What is it about?
This article provides evidence-based data from clinical trials focusing on efficacy, safety and tolerability of nintedanib for treatment of IPF
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
This article includes the update data from post-marketing reports and real world practices. Role of nintedanib in fibrosing interstitial lung diseases is also briefly mentioned.
Perspectives
I think this article would make you better understand the medication and more confident using it in your clinical practice.
Amornpun Wongkarnjana
McMaster University
Read the Original
This page is a summary of: Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update, Expert Review of Respiratory Medicine, October 2019, Taylor & Francis,
DOI: 10.1080/17476348.2019.1673733.
You can read the full text:
Contributors
The following have contributed to this page
